CAM
AMRI

ClariVest Asset Management’s Albany Molecular Research Inc AMRI Stock Holding History

ClariVest Asset Management’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-57,563
Closed -$580K – 701
2013
Q4 		$580K Sell
57,563
-1,419
-2% -$17.1K 0.02% 266
2013
Q3 		$760K Buy
58,982
+36,035
+157% +$443K 0.03% 235
2013
Q2 		$272K Buy
+22,947
New +$249K 0.01% 304

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
ACM
American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

ClariVest Asset Management's AMRI Position: Q1 2014 in Review

ClariVest Asset Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2014, closing a stake of 57,563 shares — an estimated $580K sold.

ClariVest Asset Management first reported a position in AMRI in Q2 2013 and held it in 3 quarters. The position peaked at $760K in Q3 2013. 113 funds tracked by Wall St. Rank hold AMRI as of Q1 2014.

  • ClariVest Asset Management reported no remaining Albany Molecular Research Inc position as of Q1 2014 after selling out during the quarter.
  • ClariVest Asset Management sold 57,563 Albany Molecular Research Inc shares in Q1 2014, an estimated $580K.
  • ClariVest Asset Management first reported a position in Albany Molecular Research Inc in Q2 2013 and held it in 3 quarters.
  • ClariVest Asset Management's Albany Molecular Research Inc position peaked at $760K in Q3 2013.
  • 113 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2014.

Based on ClariVest Asset Management's 13F filing for Q1 2014, filed 6 May 2014.